If you’re one of the 10,000 people in the USA diagnosed or a family member of one of the 17,000 patients that die each year from this horrific and incurable brain cancer, there is no cause with greater urgency. Nearly all patients diagnosed die within 12-18 months.
Some cancers, including brain cancer, have been historically underfunded despite the grim prognosis for those patients diagnosed. No doubt this is a direct corollary to why some cancers, like glioblastoma, have relatively few to no treatment options.
Research shows that 80% of the instances of recurrence, which are inevitable, appear in the tissue surrounding the resection cavity. The blood-brain barrier imposes biological limitations that make it easier for cancerous cells to invade the brain than it is for them to exit the brain and metastasize elsewhere. That sounds almost encouraging until you begin to discuss drug delivery: most therapeutics have high molecular weights beyond the range suitable for drug transport. Check point inhibitors which modulate biological pathways are generally effective in the treatment of most diseases: not so for glioblastoma.
Targeted delivery using nanoparticles to transport highly selective inhibitors across the blood-brain barrier remains the next frontier for treatment. “Glioblastoma requires an arsenal to combat,” said Dr. TBD, “we view the combination of improved targeting with localized delivery of specific inhibitors designed to penetrate the blood-brain barrier, potentially with radioactivated nanoparticles, as a novel modality worthy of further exploration.” GCT has recently acquired two patents for medicinal compounds that are known to cross the blood-brain barrier: PI3K and Vps34 act in mechanistically distinct manners as potent inhibitors of pathways commonly associated with cancers.
Dr. Ekokobe Fonkem, director of neuro-oncology and an associate professor and chair in the Department of Neurology at Barrow Neurological Institute.
The future of treatment
“Indeed, transport across the blood-brain barrier has been a fantasy of neurologists for some time. Delivering inhibitors like PI3K and Vps34 directly to the brain tumor with timed precision is an incredibly exciting approach, one that I’m personally honored to be involved in exploring.”
The other inhibitor acquired by GCT targets Vps34, a PI3K isoform known to affect cellular mobility and autophagy. Inhibitors of Vps34 have been shown to impede the movement of cancerous cells and their ability to induce the “suicide” of surrounding healthy cells.
Deducing how these inhibitors behave in glioblastoma patients requires further research. The ability to penetrate the blood-brain barrier is, in of itself, a tremendous advantage. Uilizing that advantage to commercialize the targeted delivery of a therapeutic payload directly to the glioma mass within the brain is where GCT is focusing its efforts.
To sum up – there is an urgent need for novel treatments of glioblastoma. And several are in development.
“Global Cancer Technology has the only radioactivated drug transport technology of its kind in the world. When successfully commercialized, the company will significantly impact cancer treatment outcomes and establish itself as a leader in this cancer treatment delivery market,” stated Dr. Santosh Kesari, world-renowned Neuro-Oncologist at John Wayne Cancer Institute.
Global Cancer Technology has numerous patents and other IP that might lead to breakthroughs in cancer therapy. The company is partnering with highly acclaimed academic institutions such as Barrow Neurological Institute, UCSD and the University of Washington, along with industry leaders, to make these therapies available to patients as quickly as possible. Global Cancer Technology’s lead cancer technology is its remote-controlled cancer drug delivery platform.
Learn more about Global Cancer Technology's remote-controlled cancer drug delivery platform by clicking here.
Dr. Chad Quarles, professor Barrow Neurological Institute
Blocking cancer in its tracks
“Phosphatidylinositol 3-kinase (PI3K) is associated with cellular processes including cell death, protein synthesis and metabolism. PI3K has been shown to block this aberrant activity. Given the number of multimodal imaging methods that we are currently deploying to improve disease characterization and detection, particularly for brain cancers, we are eager to study how this inhibitor affects the progression of brain cancer.”
Need more info before becoming an investor?
Following the close of an investment round earlier this year at $1 per share, Global Cancer Technology opened a new investment round at $2 per share. Preferred pricing available for investments of $10K or more. This is your opportunity to own shares in an emerging medical technology company that is developing a patented nanotechnology treatment for both COVID-19 and cancer.